Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This intervention combines the HMG-CoA reductase inhibitor atorvastatin with a supervised, guided physical exercise program (including aerobic and resistance training) to treat metastatic cancers. Investigated by Tampere University Hospital in the Phase 3 MOVES trial, the combination aims to modify the cancer microenvironment and metabolism to enhance the effectiveness of standard oncological treatments. Atorvastatin, a small molecule statin, inhibits cholesterol biosynthesis, while the exercise component is designed to improve patient outcomes and potentially synergistic therapeutic responses in metastatic breast, kidney, ovarian, and prostate cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + guided physical exercise.